introduction
In the field of oncology, many promising new drugs illustrate a new era of cancer drug development based on better knowledge of tumor biology. Phase II trials represent one of the key elements of this progress. Their main objective is to demonstrate preliminary evidence of efficacy and acceptable toxicity. Accurate reporting of phase II trials is thus crucial. Indeed, such publications may represent the basis to test innovative clinical hypotheses and provide data for the rationale of future phase III, randomized, controlled trials (RCTs).
In a study based on 1997 phase II published trials, Mariani et al. [1] showed that only 20% of phase II reports described the statistical design and the results clearly. Strikingly, the authors *Correspondence to: Dr Antoine Italiano, Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France. Tel: +33-05-56-33-32-44; Fax: +33-05-56-33-33-83; E-mail: a.italiano@bordeaux.unicancer.fr found that positive findings emerged less frequently from trials reporting statistical design than from those not reporting.
The dramatic increase in promising new agents and the large number of institutions involved in clinical research has led to an explosion of phase II trials. However, for most phase II trials, success does not accurately predict for phase III success [2] . This concern has influenced editorial policies of some oncology journals regarding the reporting of phase II trials [3] . Unlike phase III RCT for whom methodological recommendations for publication are available ( Consolidated Standards of Reporting Trials, CONSORT) [4] since the mid-1990s, which have improved reporting of phase III RCT [5] , no recommendations are currently available for phase II trials. The aim of this study was to assess the quality of reporting of phase II clinical trials by focusing on publications in highly ranked oncology journals. We also investigate factors associated with better reporting quality and suggest guidelines for authors to improve their reports and to facilitate readers' interpretation and critical comment of phase II trial results.
patients and methods

study selection
We selected all the peer-reviewed general oncology journals published in English with a 2011 5-year impact factor (IF) >4 [6] . They were Annals of Oncology (Ann Oncol), British Journal of Cancer (Br J Cancer), Clinical Cancer Research (Clin Cancer Res), European Journal of Cancer (Eur J Cancer), Journal of Clinical Oncology (J Clin Oncol), Journal of the National Cancer Institute (J Natl Cancer Inst), Lancet Oncology (Lancet Oncol), and The Oncologist (Oncologist). We reviewed table of contents for all volumes of the journals published between January and December 2011, identifying phase II trials assessing the efficacy and/or tolerance of anticancer drugs, radiotherapy, or surgery, as a single treatment modality or in combination. Appropriate abstracts were selected to identify articles for full-text reading and evaluation. Preclinical, phase I/II, phase II/III and biomarkers studies were excluded from this analysis. We also excluded updated reports from previously published trials, review articles, and studies related to nonmalignant disease or supportive care.
rating of global reporting quality
Based on consensus among the authors, 44 items inspired from the revised CONSORT statement for randomized trials [7] and from the Guidelines for Neuro-Oncology: standards for investigational studies (GNOSIS)-reporting of phase I and phase II clinical trials [8] were compiled into a comprehensive list (Appendix 1). All items were categorized across nine subsections (Appendix 1). For each publication, we recorded the frequency of each item. Each item was scored 1 if reported and 0 if not reported or not clearly stated, giving an overall sum (the 'overall quality score': OQS) of 0-44.
rating of key methodological items
The three items for the key methodological score were selected based on a consensus between the authors. Indeed, definitions of the first end point, definition of the evaluable population for each end point, and justification of sample size were considered as highly important for avoiding interpretation bias and thus distortion in the estimation of the effect. All end points should be identified and completely defined. If relevant, the use or not of previously validated scales or consensus guidelines such as RECIST [9] and of an independent central review [10] must be indicated.
Determination of the number of participants is made to detect clinically relevant treatment effects and must be determined carefully because it enables underlying power calculations.
In contrast to phase III trials, 'intention-to-treat' analysis is not necessarily required in phase II studies where analysis can be restricted to participants who fulfill the protocol. Whatever the statistical plan used, the population assessable for each end point should be given allowing easy identification of the characteristics of the population to whom the trial results and treatment tested applies.
A score of 1 is given for each of the three following variables 'first end point', 'sample size', and 'evaluable population' if clearly provided. The KMS was calculated for each publication by combining the scores of these three factors (range: 0-3).
statistical analysis
A standardized data collection form was created to extract data from each article. The data collection form was first tested by four coauthors (TG, APM, SMP, and AI), using a common set of five articles. After finalization and approval of the form, all articles were evaluated by two reviewers (TG and APM). Reproducibility of the results was estimated using the Cohen's kappa (κ) index for 20 randomly selected articles. The κ coefficient ranged from 0.62 to 1 for all selected items evaluated indicating good agreement between the reviewers. Qualitative variables were described using rates and proportions. The OQS, its 9 subsections scores, and the KMS were described using the median, interquartile range, minimum, and maximum values. Univariate and multivariate regression analyses were carried out to identify factors significantly associated with the OQS (global and by section) and the KMS. The variables included in these analyses were: high (>10) versus moderate/low IF; clinical trial registration in clinicaltrials.gov; type of trial (industry or academic); geographic zone (US A, Europe, transcontinental, or other); population under study (adults only versus adults and children); cancer type (solid tumor or hematological neoplasm); type of treatment (systemic treatment versus other treatment); route of administration (oral or i.v.). Variables significant at a 10% level in the univariate models were included in a multivariate regression model. Variables significant at the 5% level in the final multivariate model were considered as significant predictors. Statistical analyses were carried out using the SAS software, version 9.2 (SAS Institute, Inc., Cary, NC).
results eligible studies characteristics
One hundred fifty-eight articles were identified from table of contents. After abstract reading, two were excluded: one reporting on a phase I/II trial and the other on a biomarker-oriented study. A total of 156 articles were thus considered eligible and included in the final analysis ( Table 1 ). The majority of the publications were from two journals: J Clin Oncol and Ann Oncol. No publications were found published in J Natl Cancer Inst. Most publications reported results of studies including adults with solid tumors, managed with i.v. systemic treatments and funded by the pharmaceutical industry. Reports were well balanced in terms of geographical distribution between North America and Europe. Only 27.6% (N = 43) of articles were reported as declared on the clinicaltrials.gov registry, and 28.2% (N = 44) of the trials were randomized.
overall quality rating (OQS)
The median OQS was 28 on 44 items with a maximum score of 35 ( Table 2) . Analysis of the OQS subscores showed that reporting of statistical methods (six items) was particularly low with a median of 3, and only 18.6% of the publications reporting more than three items. About 25% of the articles did not report any study objectives (24.4%). The highest ratio score for subsections was observed for the 'study rationale' section (three items) with a mean ratio of 80%. Only 31.8% of the articles published in very high IF journals (N = 66) had a OQG >30.
rating of key methodological items
The median KMS was 2 with only 16.1% of the articles reporting all three items and almost a third reporting <1 item (31.4%) ( Tables 2 and 3 ). (Table 4) .
discussion
Quality of reporting of phase II trials in oncology remains poor even in highly ranked journals. As well as describing a low OQS, our results also show that crucial points, mandatory for an accurate interpretation of data by readers, are described in only a fraction of papers. On average, only one of the two 'end points description' items and three of the six 'statistical methods' items were reported. Although a clear definition of primary (and secondary where appropriate) outcome measures are crucial for the interpretation of phase II trials, this item was reported accurately in only 35% of articles. Our results showed that only 16% of the articles reported the three KMS items. Among them, definition of the evaluable populations for the different end points was the most infrequently reported with only 33% of the papers clearly describing this aspect. This issue is clearly relevant in the area of targeted therapies. Indeed, the majority of such drugs are administered orally every day or several days a month. This raises the question of who is assessable for efficacy analyses. In the context of phase III trials, excluding patients after randomization may introduce noncomparability of characteristics across treatment groups leading to bias and is consequently not recommended. However, in the context of phase II studies, it may be justified, for example, to exclude from efficacy analysis patients who did not start treatment received only a few doses of an oral targeted therapy, or were ineligible because they were mistakenly enrolled. This has to be clearly planned in the study protocol and reported in the publication. Although the best design of phase II studies in oncology is still a matter of debate [11] [12] [13] [14] , our findings indicate that reporting of design remains to be improved. Reporting of clinicaltrials.gov items was found to be predictive of a good OQS. In 2005, the International Committee of Medical Journal Editors first published its statement requiring registration as a precondition for publication [15] . Such registration is supposed to prevent research misconduct, specifically selective reporting, by putting key protocol information in the public domain. However, the quality of the registered data is not guaranteed. Only 27% of the phase II papers published in 2011 and analyzed in our study indicated the registration of the study through the International Clinical Trials Registry Platform (ICTRP, clinicaltrials.gov) in their publications. Besides clinicaltrials.gov registration reporting, our analysis revealed that higher IF was significantly associated with better reporting of statistical methods and results even if phase II published in very high IF journals remain poorly reported. High IF has also already been found associated with better reporting quality of randomized trials [16, 17] . One explanation for this result may be a more rigorous peer-review process or simply that better-written papers are more likely to be accepted for publication in higher impact journals. Moreover, a study showed that phase II studies were more likely to be published in low IF journals (IF <3) than phase III studies mainly because of poor methodological quality [18] . Altogether, our findings indicate the lack of improvement over time of the quality of reporting of phase II trials. Indeed, Thezenas et al. [19] showed that sample size was reported in only 76.9% of articles published in 1995 compared with 77.6% in our examination of articles published in 2011. When faced with disappointing results of a study, authors may be also tempted to embellish them. For instance, Allegro et al. [20] have recently shown that 26.2% of the phase II trials published in 2006 and 2007 were presented as positive in the conclusion of the papers, while they were in fact negative. Our results indicate that even highly ranked oncology journals do not guaranty readers to reach an independent opinion about the scientific merit of a clinical trial.
There are several limitations to our study. The reporting quality score was used for the first time and can be criticized. However, this score is largely inspired form the CONSORT checklist, the reproducibility of which has been already suggested in previous studies. We did not measure phase II methodological quality directly from study's protocol. It has been shown that there are sometimes discordances between the use of adequate research methods and the actual reporting of them [21, 22] . Since important methodological criteria may be omitted in published reports although adequately carried out, the quality of reporting should be taken only as an imperfect surrogate of true methodological quality of trials. Nevertheless, published reports are the major source for clinicians to judge the validity of the results, making the quality of the report essential. At the time of writing, only two journals from our selected panel (J Clin Oncol and Lancet Oncol) require the last version of the study protocol to be accessible online for peer reviewers and readers [23, 24] . We believe that all journals publishing phase II studies should endorse such requirements and spread adoption of the SPIRIT 2013 statement [25] , recent update of recommendation for clinical trial protocol drafting. This is even more important in the light of current space limitations in most journals. Indeed, all of our selected journals limit the number of words for articles.
Some authors have tried to promote reporting recommendations for each area of health research and have established the EQUATOR (Enhancing the Quality and Transparency Of Health Research) network [26] with a website providing links to existing recommendations. At the time of writing, there are no standard guidelines for phase II reporting. We propose to authors, reviewers, and editors to use the 44-item checklist we have developed to improve reporting of these studies which are crucial to accurately select drugs worthwhile for future testing in phase III studies in oncology. 
